We then treated the human AR+, hormone-sensitive prostate cancer cell lines LNCaP (Figure 1a) and LAPC4 (Supplementary Figure 1A), as well as the CRPC-derivative C4-2 (Figure 1b) and 22Rv1 (Supplementary Figure 1B) cell models with 6AN and observed that this drug caused a significant decrease in cell growth. The gene discussed is AR; the disease is prostate cancer.